Selecta Biosciences intends to raise $50m through private placement of shares of its common stock to be subscribed to by new and existing institutional investors and one of the company’s board of directors. 

Proceeds will be used for ongoing clinical development of SEL-212, the company’s candidate for the treatment of chronic severe gout, and to bring additional product candidates to clinical development. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

bluebird bio has offered 3.81 million shares of its common stock at a price of $105 each in a public offering to raise gross proceeds of $400.05m. 

Proceeds will be used to co-develop and co-promote bb2121 product candidate for the planned Phase I clinical study of bb21217 product candidate and for other research and development purposes. 

TransGenic and Immuno-Biological Laboratories have signed a new research agreement regarding Alzheimer's disease therapeutic drugs. 

See Also:

The agreement also includes investigation of the toxic amyloid ß42 (Aß42) using TransGenic’s model mouse, which will evaluate the drug’s effectiveness and efficacy and will also study the feasibility of developing it as a pharmaceutical product. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"bluebird bio has offered 3.81 million shares of its common stock at a price of $105 each in a public offering to raise gross proceeds of $400.05m."

CanBas has signed a joint research agreement with imaging and information solutions provider Fujifilm regarding an anti-cancer drug using peptide. 

The agreement enables CanBas to leverage its expertise in discovery studies of anticancer drug candidates using peptides to evaluate the efficacy of candidate compounds synthesised and designed by Dr Film.

Eloxx Pharmaceuticals has closed a $6m financing round in a series C venture financing led by Phil Frost, OPKO Health Inc. and Pontifax.

It brings the total gross proceeds raised by the company to $30m, has also seen participation from Korea Investment Partners, Dsc Investments LLC and Sevion Therapeutics Inc. 

Minerva Neurosciences has announced a public offering of five million shares of its common stock along with a 30-day option to the underwriters to buy up to 750,000 additional shares to cover over-allotments, if any. 

Proceeds will be used to support the ongoing clinical development of MIN-101, MIN-117, MIN-202 and MIN-301 and for other working capital and general corporate purposes.